|
US20030044409A1
(en)
|
2001-05-01 |
2003-03-06 |
Carson Dennis A. |
Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
|
|
PL2157192T3
(pl)
|
2003-10-10 |
2014-01-31 |
Deutsches Krebsforsch |
Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
|
|
DE102004050620A1
(de)
|
2004-10-13 |
2006-04-20 |
Eberhard-Karls-Universität Tübingen |
Monoklonaler Antikörper gegen Frizzled-Rezeptoren
|
|
DE102005035568A1
(de)
|
2005-07-25 |
2007-02-01 |
M-Phasys Gmbh |
Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
CN101573383B
(zh)
|
2006-06-21 |
2015-05-13 |
肿瘤疗法科学股份有限公司 |
靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途
|
|
AU2007285217B2
(en)
|
2006-08-14 |
2013-02-07 |
Forerunner Pharma Research Co., Ltd |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
|
WO2008093646A1
(ja)
|
2007-02-01 |
2008-08-07 |
National University Corporation NARA Institute of Science and Technology |
Wntシグナル伝達系活性化ペプチド
|
|
CN103002911B
(zh)
|
2008-09-26 |
2015-08-26 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
ES2579909T3
(es)
|
2009-02-03 |
2016-08-17 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
|
|
EP2412800A1
(en)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Liver organoid, uses thereof and culture method for obtaining them
|
|
WO2010092457A1
(en)
|
2009-02-10 |
2010-08-19 |
Nokia Corporation |
Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
|
|
EP2305274A1
(en)
|
2009-09-21 |
2011-04-06 |
Centre National de la Recherche Scientifique (CNRS) |
Use of WNT stimulators for treating demyelinating diseases
|
|
PT2510012T
(pt)
|
2009-12-09 |
2017-07-13 |
Bayer Pharma AG |
Anticorpos anti-c4.4a e utilizações dos mesmos
|
|
CA2794674A1
(en)
|
2010-04-01 |
2011-10-06 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
|
CA2796464C
(en)
|
2010-04-16 |
2021-08-03 |
Immune Disease Institute, Inc. |
Sustained polypeptide expression from synthetic, modified rnas and uses thereof
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
EP2694660B1
(en)
|
2011-04-03 |
2018-08-08 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
|
GB201106395D0
(en)
*
|
2011-04-14 |
2011-06-01 |
Hubrecht Inst |
Compounds
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
CN109111523B
(zh)
*
|
2011-10-14 |
2022-06-07 |
诺华股份有限公司 |
用于Wnt途径相关疾病的抗体和方法
|
|
WO2013071047A1
(en)
|
2011-11-11 |
2013-05-16 |
Children's Medical Center Corporation |
Compositions and methods for in vitro transcription of rna
|
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
|
EP2820151B1
(en)
|
2012-02-28 |
2020-03-25 |
Novartis AG |
Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
|
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
|
EP2882775B1
(en)
*
|
2012-08-09 |
2018-02-14 |
Roche Glycart AG |
Asgpr antibodies and uses thereof
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US20160022840A1
(en)
|
2013-03-09 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
MA39896A
(fr)
*
|
2014-04-21 |
2017-03-01 |
Abbvie Stemcentrx Llc |
Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
|
|
US11142577B2
(en)
|
2014-09-12 |
2021-10-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
WNT signaling agonist molecules
|
|
US10259874B2
(en)
|
2014-10-27 |
2019-04-16 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
CA2983008A1
(en)
|
2015-04-17 |
2016-10-20 |
Merrimack Pharmaceuticals, Inc. |
Combination treatments with seribantumab
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
AU2016365834B2
(en)
|
2015-12-08 |
2023-09-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
US20170349659A1
(en)
|
2016-06-03 |
2017-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Wnt signaling agonist molecules
|
|
US20230192896A1
(en)
*
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
WO2018107116A1
(en)
*
|
2016-12-09 |
2018-06-14 |
Abbvie Stemcentrx Llc |
Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
|
|
JP7617603B2
(ja)
|
2017-01-11 |
2025-01-20 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
|
|
JP7305543B2
(ja)
|
2017-01-26 |
2023-07-10 |
スロゼン オペレーティング， インコーポレイテッド |
組織特異的Ｗｎｔシグナル増強分子およびその使用
|
|
EP3619238A4
(en)
|
2017-05-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
CYTOTOXICITY INDUCING THERAPEUTIC
|
|
GB201708330D0
(en)
|
2017-05-24 |
2017-07-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Fusion protein for enhancing intestinal regeneration
|
|
CN111655729B
(zh)
|
2017-12-19 |
2023-10-20 |
瑟罗泽恩奥普瑞汀公司 |
抗卷曲蛋白抗体和使用方法
|
|
EP3732201A4
(en)
|
2017-12-19 |
2022-04-20 |
Surrozen Operating, Inc. |
WNT SURROGATES AND THEIR USES
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
CA3104526A1
(en)
|
2018-07-05 |
2020-01-09 |
Surrozen, Inc. |
Multi-specific wnt surrogate molecules and uses thereof
|
|
JP2021530223A
(ja)
|
2018-07-09 |
2021-11-11 |
スロゼン， インコーポレイテッド |
組織特異性Ｗｎｔシグナル増強分子及びその使用
|
|
US20220064337A1
(en)
|
2018-12-19 |
2022-03-03 |
Surrozen, Inc. |
Antigen binding formats for receptor complexes
|
|
JP7663501B2
(ja)
|
2019-02-11 |
2025-04-16 |
スロゼン オペレーティング， インコーポレイテッド |
眼障害におけるｗｎｔシグナル伝達の調節
|
|
US20220195053A1
(en)
|
2019-03-11 |
2022-06-23 |
Surrozen Operating Inc. |
Modulation of wnt signaling in gastrointestinal disorders
|
|
US20220175884A1
(en)
|
2019-04-02 |
2022-06-09 |
Surrozen Operating, Inc. |
Modulation of wnt signaling in auditory disorders
|
|
CN120025448A
(zh)
|
2019-06-11 |
2025-05-23 |
安托拉诊疗公司 |
多价fzd和wnt结合分子及其用途
|
|
US11050604B2
(en)
|
2019-07-01 |
2021-06-29 |
Rampart Communications, Inc. |
Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
|
|
CN115427446A
(zh)
|
2020-02-24 |
2022-12-02 |
瑟罗泽恩奥普瑞汀公司 |
Wnt超级激动剂
|
|
TW202233656A
(zh)
|
2020-11-16 |
2022-09-01 |
美商蘇羅森營運公司 |
肝特異性wnt訊號增強分子及其用途
|
|
JP2024509266A
(ja)
|
2021-03-10 |
2024-02-29 |
スロゼン オペレーティング， インコーポレイテッド |
胃腸障害におけるｗｎｔシグナル伝達のモジュレーション
|
|
WO2023044348A1
(en)
|
2021-09-14 |
2023-03-23 |
Surrozen Operating, Inc. |
Modulation of wnt signalling in pulmonary disorders
|
|
EP4448009A4
(en)
|
2021-12-17 |
2025-12-10 |
Surrozen Operating Inc |
WNT SUBSTITUTION AGENTS AND LACRYMAL GLAND REGENERATION METHODS
|